Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised EQT AB (publ) in connection with the listing on Nasdaq Stockholm (1)
Mandate

Vinge has advised EQT AB (publ) in connection with the listing on Nasdaq Stockholm

September 24, 2019 Capital Markets and Public M&A

Vinge has advised EQT AB (publ) (“EQT”) in connection with the offering and listing on Nasdaq Stockholm with first day of trading on 24 September 2019.

Vinge has advised EQT in connection with the listing and also with the connected reorganization. 


The Vinge team primarily consisted of Dain Hård Nevonen, Erik Sjöman, Sofie Bjärtun, Joel Wahlberg, Hampus Olsson, Joel Magnusson and Emelie Svanberg (Capital Markets), Christina Kokko, Filip Öhrner, Karl Klackenberg, Christian Brelin and Christina Odengran (M&A and Restructuring), Louise Brorsson Salomon, Josefine Larsson, Ludvig Wettergren and Pauline Lagerstrand (Banking and Finance), Mattias Schömer, Henrik Wastenson and Victor Ericsson (Tax), Marcus Glader and Emma Johansson (Competition and Regulatory) and Olof Jisland and Valter Gran (EQT Foundation).

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026